Mupirocin (lithium)

Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae) . Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis[1][2][3][4][5][6].

Product Specifications

CAS Number

[73346-79-9]

Product Name Alternative

BRL-4910A (lithium) ; Pseudomonic acid (lithium)

UNSPSC

12352005

Hazard Statement

H317

Target

Aminoacyl-tRNA Synthetase; Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Endocrinology

Assay Protocol

https://www.medchemexpress.com/mupirocin-lithium.html

Purity

97.0

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O[Li])=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2

Molecular Formula

C26H43LiO9

Molecular Weight

506.56

Precautions

H317

References & Citations

[1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27 (4) :495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6 (10) :761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42 (3) :272-5.|[4]Twilley D, et al. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. |[5]Ha KR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118 (3) :535-40. |[6]Gilbart J, et al. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993 Jan;37 (1) :32-8.